Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials

被引：0
作者：
Mattias Lorentzon
Helena Johansson
Nicholas C. Harvey
Enwu Liu
Liesbeth Vandenput
Carolyn J. Crandall
Jane A. Cauley
Meryl S. LeBoff
Eugene V. McCloskey
John A. Kanis
机构：
[1] Sahlgrenska Academy,Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine
[2] University of Gothenburg,Geriatric Medicine
[3] Sahlgrenska University Hospital Mölndal,Centre for Metabolic Bone Diseases
[4] Mary McKillop Institute for Health Research,MRC Lifecourse Epidemiology Unit
[5] Australian Catholic University,NIHR Southampton Biomedical Research Centre
[6] University of Sheffield,Department of Internal Medicine and Clinical Nutrition, Institute of Medicine
[7] University of Southampton,Department of Medicine
[8] University of Southampton and University Hospital Southampton NHS Foundation Trust,Department of Epidemiology, Graduate School of Public Health
[9] Sahlgrenska Academy,Division of Endocrinology, Diabetes and Hypertension, Department of Medicine
[10] University of Gothenburg,Mellanby Centre for Bone Research, Department of Oncology and Metabolism
[11] David Geffen School of Medicine at the University of California,Centre for Integrated Research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research
[12] University of Pittsburgh,undefined
[13] Brigham and Women’s Hospital Boston,undefined
[14] Harvard Medical School,undefined
[15] University of Sheffield,undefined
[16] University of Sheffield,undefined
来源：
Osteoporosis International | 2022年 / 33卷
关键词：
Epidemiology; Falls; Fracture risk; FRAX; Menopausal hormone therapy; Postmenopausal women; Osteoporosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2297 / 2305
页数：8
相关论文
共 166 条
[1]  
Rossouw JE(2002)Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial JAMA 288 321-333
[2]  
Anderson GL(2004)Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial JAMA 291 1701-1712
[3]  
Prentice RL(2003)Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial JAMA 290 1729-1738
[4]  
Anderson GL(2017)Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement JAMA 318 2224-2233
[5]  
Limacher M(2020)Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int 31 2271-2286
[6]  
Assaf AR(2017)Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials JAMA 318 927-938
[7]  
Cauley JA(2019)Hormone therapy for first-line management of menopausal symptoms: practical recommendations Womens Health (Lond) 15 1745506519864009-1046
[8]  
Robbins J(2007)The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos Int 18 1033-1054
[9]  
Chen Z(2009)Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049-817
[10]  
Force USPST(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811-1486
12345678910